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Abstract
Introduction: The prognostic value of HER2 expression in patients with advanced non-small cell
lung cancer remains controversial. The relationship between HER2 expression, and platinum
resistance and patient survival, was investigated.
Methods: Seventy-three consecutive patients (median age, 61 years) with stage IIIB and IV non-
small cell lung cancer, admitted between February 2004 and December 2006, were included in this
study. Sixty-one patients received gemcitabine, given as two 1250 mg/m2 doses on days 1 and 8 and,
cisplatin, given as a 75 mg/m2 dose on day 8. Twelve patients received vinorelbine, given as two 25
mg/m2 doses on day 1 and 8, and cisplatin, given as a 75 mg/m2 dose on day 1. Both treatment
paradigms were repeated on a 21-day cycle. Tumor response was evaluated by comparing tumor
size on computerized tomography scans before and after three cycles of chemotherapy. HER2
status was examined by immunohistochemical analysis of paraffin-embedded specimens.
Results: HER2 was positive in 21 of 73 patients (28.8%). Of the 21 patients with HER2 positivity,
13 (61.9%) responded to chemotherapy with either a complete response, partial remission, or
evidence of stable disease. Of 52 HER2-negative patients, 48 (92.3%) exhibited a response to
chemotherapy. The difference in response to therapy between HER2-positive and -negative
patients was statistically significant (p = 0.003). The median overall survival duration for all patients
was 13 months. Median overall survival time was 14 months for HER2-negative patients and 10
months for HER2-positive patients (log-rank p = 0.007).
Conclusion:  Non-small cell lung cancer patients with high expression of HER2 exhibited
resistance to cisplatin-based chemotherapies that are the standard treatment for this disease. Our
results indicate that HER2 status may be a predictive and prognostic factor for cisplatin- based
therapy response and disease survival.
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Introduction
Non-small-cell lung cancer (NSCLC) is a leading cause of
cancer deaths worldwide [1]. The prognosis of patients
with advanced NSCLC remains poor despite increased
understanding of the disease and therapeutic advances,
heightening the need for new therapeutic approaches.
Modern therapeutic strategies have achieved 1-year sur-
vival rates of up to 50% [2]. A combination of cisplatin or
carboplatin with third generation agents, such as gemcit-
abine, paclitaxel, docetaxel, or vinorelbine, represents the
standard of care for fit patients with advanced disease [3-
5]. However, appreciable clinical response to chemother-
apy is achieved in only 30–40% of patients, probably
because of relatively higher chemoresistance intrinsic to
NSCLC. The mechanism of this resistance is not well
understood. Resistance does not appear to correlate with
MDR1 gene expression [6], but several reports have linked
NSCLC chemoresistance to mutations in TP53 and/or
overexpression of HER2. The therapeutic efficacy of anti-
cancer agents is strongly dependent on the ability of the
drugs to trigger apoptosis in target tumor cells [7].
Because further advances in chemotherapy are likely to be
limited, the key to improving outcomes for NSCLC
patients may turn on targeted therapeutic strategies. In
particular, agents that target the epidermal growth factor
receptor (EGFR) may have a major impact on the treat-
ment of advanced NSCLC [8,9].
The HER2/neu oncogene, a probable prognostic indicator
in lung cancer patients, is a member of the EGFR family.
Also known as c-erbB-2, HER2 is encoded by a gene
located in the chromosomal region 17q11.2–q12, and
encodes a transmembrane receptor-type tyrosine-protein
kinase [10]. Dimerization of HER2/neu with an activated
EGFR molecule activates a signal transduction cascade
that leads to an increase in cell proliferation, angiogen-
esis, and metastatic potential, and a decrease in apoptosis.
HER2/neu overexpression is found more often in breast,
ovarian, and lung cancer, especially adenocarcinoma [10],
and can be detected by immunohistochemistry (IHC).
Clinical trials indicate that angiogenesis is more active in
tumor tissues in which HER2 is activated, and have sug-
gested that this may lead to platinum resistance [11,12].
Tsai and colleagues, using a panel of 20 NSCLC lines
obtained from untreated patients, found that overexpres-
sion of HER2 was a marker for intrinsic multidrug resist-
ance [6]. HER2-mediated chemoresistance depended on
the type of drug used, cell type, and HER2 expression level
[10]. The aim of the current study was to investigate the
relationship between HER2 expression in non-small cell
lung cancer patients, and to assess the effect of this expres-
sion on cisplatin-based chemoresistance.
Patients and methods
Patients
Seventy-three consecutive, previously untreated advanced
non-small cell lung cancer patients referred to Baskent
University Medical Faculty Medical Oncology Depart-
ment between February 2004 and December 2006 were
included in the study. All patients were diagnosed with
stage IIIB with pleural effusion or stage IV, according to
the American Joint Committee on Cancer staging system
(AJCC) 1997. The performance status of patients was 0–2
according to the Eastern Cooperative Oncology Group
(ECOG) scale. The studied patients included four females
and 69 males with a median age of 61 years (range, 35–78
years). Bone marrow, renal and hepatic functions were
sufficient for patients to take part in the study. Two-
dimensional lesions, measurable by radiologic imaging
and physical examination, were taken into account for fol-
low-up criteria. Patients with no measurable masses and
concomitant life-threatening diseases were not included
in the study.
Treatment
Sixty-one patients received gemcitabine, given as two
1250-mg/m2 doses on days 1 and 8 and, cisplatin, given
as a 75-mg/m2  dose on day 8 [13]. Twelve patients
received vinorelbine given as two 25-mg/m2 doses on day
1 and 8 and, cisplatin, given as a 75-mg/m2 dose on day 1.
Both gemcitabine/cisplatin and vinorelbine/cisplatin
treatment paradigms were repeated on a 21-day cycle.
Patients received a total of four to six chemotherapy
courses. Twenty patients received palliative radiotherapy;
eight received radiotherapy for bone metastases and
twelve received radiotherapy for cranial metastases before
the first chemotherapy course.
Treatment evaluation
Prior to treatment, all patients were evaluated by physical
examination, electrocardiography, chest X-ray, bone scin-
tigraphy, thorax computerized tomography (CT), and
upper abdominal ultrasound and CT; complete blood
counts were also performed. Cranial computerized tom-
ography or magnetic resonance imaging was performed in
patients with signs or symptoms of central nervous system
disease.
Tumor response was evaluated after the third chemother-
apy course by comparison of tumor size on CT scans
before and after chemotherapy. We used World Health
Organization (WHO) guidelines for response criteria
throughout the study. Objective response was defined as
follows: complete response (CR) – complete resolution of
all disease lasting at least 1 month; partial response (PR)
– a decrease ≥ 50% lasting at least 1 month; stable diseaseJournal of Experimental & Clinical Cancer Research 2009, 28:97 http://www.jeccr.com/content/28/1/97
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(SD) – a decrease of < 50% or an increase of < 25% in
lesions; and progressive disease (PD) – 25% or more
increase in the size of one or more lesions, or the appear-
ance of new lesions.
IHC
Tumor-containing tissue slices for examination by IHC
were selected from archived paraffin-embedded pathol-
ogy laboratory specimens. Five-micron thick slices were
deparaffinized, and then processed for antigenic retrieval
by suspending in a 10-mM citrate buffer solution (pH 6.0)
and boiling in a microwave oven for 5 minutes at 500 W,
5 minutes at 400 W and 5 minutes at 350 W. Specimens
were kept in a 3% hydrogen peroxide solution to remove
endogenous peroxides, and then incubated for 5 minutes
with Ultra V block (TP-125-HU, Thermo Fisher Scientific
Inc., USA) to reduce background. A solution of HER2 anti-
body (Clone e2-4001 + 3B5, Ready to Use for Immuno-
histochemical Staining, NeoMarkers/Labvision, USA) was
added drop-wise to the slices and incubated for 45 min-
utes at room temperature. After washing for 10 with Tris-
buffered saline (TBS), biotin-conjugated TP-125-HB (goat
anti-polyvalent) was applie and allowed to stand for 10
minutes. Slide- mounted slices were again washed with
TBS (10 minutes) and then incubated with streptavidin
peroxide for 15 minutes. Slices were then washed for 10
minutes with TBS, and 3-amino-9-ethylcarbazole (AEC)
chromogenic substrate (RTU lot: 065020) was added
dropwise. Slices were stored in the dark after counterstain-
ing with Mayer's Hematoxylin. Under a light microscope,
brown-red coloration in tumor cytoplasmic membranes
was considered HER2 positive. Unstained membranes
were considered negative (-); pale and partial membra-
nous staining in less than 10% of tumor cells was given a
score of 1+; pale and complete staining in more than 10%
of tumor cells was given a score of 2+; and strong and
complete staining in more than 10% of tumor cells was
given a score of 3+.
Statistical analysis
SPSS (Statistical Package for Social Sciences) version 16
was used to analyze the results. After descriptive statistical
analyses, survival curves were drawn according to the Kap-
lan Meier method. The differences between survival curves
were analyzed using log-rank tests. Chi-square tests were
used to investigate differences between proportions. The
effects of histopathology, HER2-positivity and stage of
disease on survival were investigated using a Cox Regres-
sion Model. Values of p < 0.05 were considered statisti-
cally significant.
Results
Patient characteristics
Seventy-three patients with non-small cell lung cancer
were evaluated between February 2004 and December
2006. Thirty patients (41%) had stage IIIB disease, and 43
(59%) stage IV. Histopathological types were squamous
cell carcinoma in 34 patients (46.5%), adenocarcinoma
in 27 (37%) and histopathologically non-small cell lung
cancer not otherwise specified (NOS) in 12 (16.5%).
The median follow-up time was 13 months (range, 2–44
months). At the end of follow-up, 66 patients (90.4%)
had died and 7 (9.6%) survived. During the follow-up
period, metastases were detected in bone (13 patients),
brain (10 patients), adrenal gland (2 patients), pericar-
dium (1 patient), and leptomeninges (1 patient).
HER2 expression and response to chemotherapy
Tumors were HER2-positive in 21 of 73 patients (28.8%);
of these, 5 patient specimens were scored as 1+, 10 2+ and
6 3+. IHC staining for HER2 in relation to clinical charac-
teristics of patients and histological tumor type is shown
in Table 1. There was no correlation between the expres-
sion of HER2 and the age of patients, stage of tumor, or
histological tumor type. One patient showed a complete
response (CR) to chemotherapy, and 32 patients exhib-
ited partial response (PR). Disease stabilization (SD) was
confirmed in 28 patients, and progressive disease (PD)
was manifest in 12. For purposes of statistical analysis,
CR, PR, and SD were evaluated together as a single group
and PD was evaluated separately as a second group. Of the
HER2-positive patients, 61.9% (13/21) showed a
response to chemotherapy (CR+PR+SD); among HER2-
negative patients, 92.3% (48/52) responded to chemo-
therapy. The response to therapy was significantly lower
in HER2-positive patients than in HER2-negative patients
(p = 0.003, chi-squared test; Table 2). There was no corre-
lation between the response to chemotherapy and clinical
characteristics of patients, stage of tumor, or histological
type (Table 3).
Table 1: Immunohistochemical staining for HER 2 according to 
clinical characteristics of patients, stage and histological type of 
tumor
Patient characteristics Number of patients HER 2 +(%)
Total Patients 73 21 (28.8)
Sex
Male 69 19 (27.5)
Female 4 2 (50)
Stage
Stage IIIB 30 9 (30)
Stage IV 43 12 (27.9)
Histopathology
Adenocarcinoma 27 11 (40.7)
Squamous cell (Epidermoid) 34 5 (14.7)
Not otherwise specified (NOS) 12 5 (41.6)Journal of Experimental & Clinical Cancer Research 2009, 28:97 http://www.jeccr.com/content/28/1/97
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Survival
Median overall survival for all 73 patients was 13 months.
For Her2-negative patients, median overall survival was
14 months, whereas for HER2-positive patients, median
overall survival was 10 months, a difference that was sta-
tistically significant (p = 0.007, log-rank test). Survival
curves are shown in Figure 1. One-year survival probabil-
ities were 76.9% for HER2-negative patients and 42.9%
for HER2-positive patients; the corresponding 2-year sur-
vival rates were 51.9% and 0%, respectively.
Cox's regression analyses
After correcting for age, gender, and stage, HER2 positivity
was found to increase the individual death risk by 2.104-
fold (95% CI: 1.206–3.670; p = 0.009).
Discussion
In this study, we detected HER2 overexpression in 22 of
73 tumors (28.8%) using immunohistochemistry. The
mean percentage of non-small cell lung carcinomas
reported to overexpress HER2 ranges from 18–55%, with
an average of 31% [14]. This diversity of results probably
reflects differences in methodologies, which have
included flow cytometry, IHC, and Western blotting.
Moreover, the cut-off point for HER2 positivity varied
among studies, ranging from 5% to 10% [15,16]. In our
study, we used 10% as the cut-off point. Patients with a
HER2 positivity score of +1 to +3 by IHC staining criteria
were defined as HER2-positive. The frequency of HER2
staining differed among non-small cell lung cancer sub-
types, and was much higher for adenocarcinoma than for
squamous or large-cell carcinomas [14-17]. We observed
similar results in our study.
Trastuzumab, a monoclonal antibody that binds to HER2,
was originally developed for use against breast cancer.
Recently, a number of phase II trials have been conducted
to evaluate the response of NSCLC to trastuzumab [18].
Some of these trials enrolled lung cancer patients with +2
or +3 HER2 expression scores; however, others included
patients with tumor HER2-positive scores of +1 to +3 [18].
Because of these differences in enrollment criteria, it is not
clear to what degree HER2 overexpression is a prerequisite
for trastuzumab effectiveness.
There have been conflicting reports on the prognostic
value of HER2 overexpression. Recently, Nakamura and
colleagues published a meta-analysis to assess the associ-
ation of HER2 overexpression with prognosis in NSCLC
[19]. A total of 2,579 patients were included in the final
analysis, which concluded that survival at 3 and 5 years
was significantly poorer in patients with HER2 overex-
pression [19].
Different hypotheses have been proposed to explain the
poor prognosis of patients with HER2-overexpressing
tumor cells. One suggestion is the intrinsic resistance to
cytotoxic agents is high in HER2-expressing tumor cells. It
is known that high levels of HER2 expression in breast
cancer predict resistance to adjuvant chemotherapy [20],
and HER2 overexpression has been associated with poor
prognosis in breast cancer [21]. The intrinsic chemoresist-
ance of HER2-overexpressing NSCLC lines was investi-
Table 2: Response to chemoterapy according to expression of 
HER 2
HER 2 CR+PR+SD PD
HER 2 (+) 13 (63.9) 8(38.1%)
HER 2 (-) 48 (92.3%) 4(7.7%)
Table 3: Response to chemoterapy according to clinical characteristics of patients and histological type of tumor
Patient characteristics Number of patients CR+PR+SD PD
Total Patients 73 61(83.6%) 12 (16.4%)
Sex
Male 69 58 (84%) 11 (16%)
Female 4 3(75%) 1 (25%)
Stage
Stage IIIB 30 29(96.6%) 1(3.4%)
Stage IV 43 32 (74.4%) 11 (25.6%)
Histopathology
Adenocarcinoma 27 21(78%) 6(22%)
Squamous cell (Epidermoid) 34 31(91.2%) 3 (8.8%)
Not otherwise specified (NOS) 12 9 (75%) 3 (25%)Journal of Experimental & Clinical Cancer Research 2009, 28:97 http://www.jeccr.com/content/28/1/97
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gated by Tsai and associates, who showed that resistance
to the cytotoxicity of doxorubicin and cisplatin increased
with greater expression of HER2 [6].
Recently, investigations into the relationship between p53
and HER2 expression, and response to neoadjuvant
chemotherapy, in resected lung cancer demonstrated a
tendency toward chemoresistance in tumors with a high
level of HER2 expression [16]. Although cisplatin-based
combination chemotherapies are the standard treatment
for NSCLC [3], our study clearly showed a lower response
to cisplatin-based chemotherapy in HER2-positive
patients than in HER2-negative patients. The median
overall survival was also reduced in HER2-positive
patients. These results suggest that NSCLC patients with
HER2-overexpressing tumors may require a more potent
chemotherapy regimen to achieve longer survival. HER2
status thus seems to be both a predictive and a prognostic
factor for cisplatin- based therapy response and disease
survival.
Immunohistochemistry is a commonly used method to
detect HER2 in different tumor types. Fluorescence in situ
hybridization (FISH), another method often used to eval-
uate HER2 status, mainly determines HER2 gene copy
number [22]. Recently, comparisons of IHC and FISH
techniques in breast cancer have shown that FISH is more
specific than IHC [22]. In NSCLC, the optimal technique
for showing HER2 overexpression has not yet been deter-
mined. Unlike the situation in breast cancer, HER2 over-
expression in NSCLC is more likely caused by
chromosomal duplication rather than gene amplification
[23]. Recently, Kuyama and co-workers investigated the
relationship between HER2 expression and treatment out-
come in locally advanced lung carcinoma using both
methodologies [24]. The HER2-FISH results were margin-
ally correlated with IHC results, and only the HER2-FISH
data were determined to be an independent factor for
poor prognosis of cisplatin-based chemotherapy and sur-
vival [24]. In our study, we measured HER2 protein
expression by IHC. Although FISH results are demonstra-
bly better for determining HER2 status in breast cancer,
until it becomes clear which method is better for evaluat-
ing HER2 status in NSCLC, IHC remains a widely availa-
ble, simple, and less expensive method for determining
HER2 expression.
Conclusion
Despite advances in chemotherapy, the prognosis for
NSCLC patients remains poor. Many factors, including
HER2 overexpression, may contribute to this adverse out-
come Only a few studies have correlated HER2 status and
cisplatin-based chemotherapy resistance. Here, we
showed that advanced NSCLC that express a high level of
HER2 are resistant to cisplatin-based chemotherapies,
which are the standard for this disease. HER2 status thus
appears to represent both a predictive and prognostic fac-
tor for advanced NSCLC.
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